Dr. Auliya Suwantika is Professor of Pharmacoeconomics
and Dean of Pharmacy, Faculty of Pharmacy, Universitas
Padjadjaran,
Indonesia. He is also Chair of Indonesian Health
Technology Assessment Committee, Ministry of Health of the Republic of
Indonesia. He holds PhD in Pharmacoeconomics from University of
Groningen Netherlands. His research is focused on economic evaluations of new
healthcare interventions in low- and middle-income countries, including
adequate coverage for maternal, newborn, child, adolescent health and
nutrition. These evaluations enable a comprehensive approach to the
decision-making process by considering the role of multiple stakeholders (e.g.,
government, healthcare provider, and payer). Through his work, he has been
appointed to be a member of the Indonesian Technical Advisory Group on
Immunization (ITAGI) health economics working group and the Indonesian National
Drug Formulary Committee. He is also a member of the Strengthening Active
Partnerships for Policy and Health Intervention Research and Evaluation
(SAPPHIRE) Advisory Committee, which is focused on activities to strengthen
health technology assessment of new healthcare interventions in Asia.
Dr. Auliya Suwantika is Professor of Pharmacoeconomics
and Dean of Pharmacy, Faculty of Pharmacy, Universitas
Padjadjaran,
Indonesia. He is also Chair of Indonesian Health
Technology Assessment Committee, Ministry of Health of the Republic of
Indonesia. He holds PhD in Pharmacoeconomics from University of
Groningen Netherlands. His research is focused on economic evaluations of new
healthcare interventions in low- and middle-income countries, including
adequate coverage for maternal, newborn, child, adolescent health and
nutrition. These evaluations enable a comprehensive approach to the
decision-making process by considering the role of multiple stakeholders (e.g.,
government, healthcare provider, and payer). Through his work, he has been
appointed to be a member of the Indonesian Technical Advisory Group on
Immunization (ITAGI) health economics working group and the Indonesian National
Drug Formulary Committee. He is also a member of the Strengthening Active
Partnerships for Policy and Health Intervention Research and Evaluation
(SAPPHIRE) Advisory Committee, which is focused on activities to strengthen
health technology assessment of new healthcare interventions in Asia.